Skip to Content
Merck
All Photos(1)

Documents

D2850000

Dipyridamole

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H40N8O4
CAS Number:
58-32-2
Molecular Weight:
504.63
MDL number:
MFCD00010555
UNSPSC Code:
41116107
PubChem Substance ID:
329798756
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

dipyridamole

manufacturer/tradename

EDQM

mp

165-166 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

InChI key

IZEKFCXSFNUWAM-UHFFFAOYSA-N

Gene Information

human ... PDE10A(10846) , PDE1A(5136) , PDE1B(5153) , PDE1C(5137) , PDE2A(5138) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144) , PDE5A(8654) , PDE6A(5145) , PDE6B(5158) , PDE6C(5146) , PDE6D(5147) , PDE6G(5148) , PDE6H(5149) , PDE7A(5150) , PDE7B(27115) , PDE8A(5151) , PDE8B(8622) , PDE9A(5152) , SLC29A1(2030)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dipyridamole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000802

Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard

1220506

Dipyridamole, United States Pharmacopeia (USP) Reference Standard

1220517

Dipyridamole Related Compound A, United States Pharmacopeia (USP) Reference Standard

1220561

Dipyridamole Related Compound F, United States Pharmacopeia (USP) Reference Standard

1220528

Dipyridamole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1220539

Dipyridamole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1220540

Dipyridamole Related Compound D, United States Pharmacopeia (USP) Reference Standard

1220559

Dipyridamole Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP131

Dipyridamole, British Pharmacopoeia (BP) Reference Standard

BP1102

Dipyridamole impurity standard, British Pharmacopoeia (BP) Reference Standard

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Greenhalgh et al.
Health technology assessment (Winchester, England), 15(31), 1-178 (2011-09-06)
Occlusive vascular events such as myocardial infarction (MI), ischaemic stroke and transient ischaemic attack (TIA) are the result of a reduction in blood flow associated with an artery becoming narrow or blocked through atherosclerosis and atherothrombosis. Peripheral arterial disease is
Subrata Chakrabarti et al.
Vascular pharmacology, 48(4-6), 143-149 (2008-03-18)
Stroke is a leading cause of morbidity and mortality and the most common cause of neurological disability in older individuals. Prevention of recurrent stroke includes risk factor modification as well as the use of therapies that inhibit platelet activation. One
E L L M De Schryver et al.
The Cochrane database of systematic reviews, (2)(2), CD001820-CD001820 (2006-04-21)
Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk-reduction compared with
Hyung-Hwan Kim et al.
Arteriosclerosis, thrombosis, and vascular biology, 28(3), s39-s42 (2008-01-05)
Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively. By increasing cAMP and cGMP levels in platelets, DP reversibly
Djeven P Deva et al.
Cardiology in the young, 24(5), 822-830 (2013-09-21)
Vasodilator stress perfusion cardiovascular magnetic resonance imaging is a clinically useful tool for detection of clinically significant myocardial ischaemia in adults. We report our 5-year retrospective experience with perfusion cardiovascular magnetic resonance in a large, quarternary adult congenital heart disease
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service